An Open-Label, Multi-Center, Phase IB Study of RO7082859 and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; RO 7082859 (Primary) ; Obinutuzumab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 06 Nov 2019 Results (n=38; as of 25 Jun 2019) released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 01 Oct 2019 Planned End Date changed from 24 Aug 2021 to 23 Aug 2021.
- 01 Oct 2019 Planned primary completion date changed from 24 Aug 2021 to 23 Aug 2021.